Health Secretary Neil Gray has been furiously condemned for failing to ensure access to a new muscular dystrophy drug for ...

The CHMP recommends conditional marketing authorization for Duvyzat to treat Duchenne muscular dystrophy in patients aged 6 ...

From STAT’s Adam Feuerstein: The FDA informed Capricor Therapeutics that a meeting of outside experts will be convened to ...

Practical pain relief strategies for people with DMD and their caregivers, covering daily care, medications, and emotional ...

Sarepta has submitted a request to the FDA to include the death case in Elevidys’ label, and the agency plans to review the ...

While there have been reports from drugmakers about possible interruptions with FDA matters due to staff layoffs, one company ...

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular ...

A new study led by researchers at Hospital for Special Surgery (HSS) suggests that currently available therapies may help ...

9 The period of treatment was twelve months ... He believed that the underlying molecular defect in Duchenne muscular dystrophy was affected by physical activity which hastened the deterioration ...

A regulatory committee has recommended that Duvyzat be approved in the European Union as a treatment for Duchenne muscular ...

Duchenne muscular dystrophy (DMD) in India faces challenges in diagnosis, treatment, and support, highlighting the urgent ...

Cas12Max-based gene editing therapy for Duchenne muscular dystrophy, one of the most severe forms of the inherited muscular dystrophies that affects primarily boys. Huidagene Therapeutics and ...